TG Therapeutics Announces Phase I Study of Novel BTK inhibitor, TG-1701, in Patients with Relapsed or Refractory B-cell Malignancies is Open for Enrollment
Go back to TG Therapeutics Announces Phase I Study of Novel BTK inhibitor, TG-1701, in Patients with Relapsed or Refractory B-cell Malignancies is Open for Enrollment| TG THERAP (NASDAQ: TGTX) | Delayed: 54.40 +1.18 (2.22%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $53.22 | 52 Week High | $14.87 | |||
| Open | $54.61 | 52 Week Low | $4.90 | |||
| Day High | $57.38 | P/E | N/A | |||
| Day Low | $54.25 | EPS | $-0.67 | |||
| Volume | 3,951,267 | |||||
